Similarly, OS and recurrence-free survival (RFS) did not differ for patients with high or low EIF4G2 expression when analyzed by tumor type (Supplementary Fig. S1B, C) or tumor stage (Supplementary Fig. S1D, E). This evidence concerns the gene EIF4G2 and neoplasm.